Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
R&D Analysis
- Home
- consulting
- r and d analysis
R&D efficiency is often calculated through the return on investments made on therapeutic candidates when they reach their commercialization stage and can earn revenue for the company that has developed it.
- Such efficiency, however, has been declining in the Pharma R&D sector, which propels decision-makers and CXOs to assess their portfolios' relevancy in the early development stage.
- Assessing portfolio risk through assessment of candidate’s projected success and understanding ways of reducing cost of R&D are some ways which can help benchmark candidates of interest against the market parameters of success.
- Moreover, understanding competition at an early stage creates a foundation for assessing future market shares and deciding the candidate’s potential niche area in the market.
Our Perspective
The most basic way to understand the candidate’s journey through preclinical and clinical development is by assessing the exact parameters of other candidates already in the space. To help pharmaceutical companies evaluate the current scenario of a particular indication, Mechanism of Action, Active Pharmaceutical Ingredient, or a particular Drug candidate, etc. DelveInsight’s insight-packed reports clarify uncertainties and challenge blind spots to provide timely intelligence to the company.
Our R&D Analysis Service Provides:
- Comparative analysis
- A drug candidate’s overall developmental landscape
- In-depth insights on regulatory milestones
- Therapeutic assessment
- Details of asset-based collaborations and partnerships
- Developmental milestones of therapies of a particular indication, MoA, API, etc.